Novartis launches program with Biofourmis for AI monitoring of heart failure patients

Andrea Park - Print  | 

Novartis has selected artificial intelligence-powered digital therapeutics company Biofourmis for a commercial project leveraging predictive analytics for early intervention in patients with low ejection fraction.

Throughout the three-month program, recently discharged heart failure patients will use a wearable biosensor and accompanying app to track symptoms, manage medications and communicate with care teams. Biofourmis' artificial intelligence-powered Biovitals Analytics Engine will continuously process patient data captured by the app to predict exacerbation of the patients' cardiac conditions in advance and provide care teams with suggestions for early intervention.

The project is similar to another one currently in the works at the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation. Announced in July, that study will use the Biovitals platform to determine how heart failure patients' functional capacity and quality of life affect the drug approval process.

More articles on AI:
AI to have major effects on better-paid, higher-educated workers: 5 things to know
AI not likely to replace physicians, experts say
Novant Health deploys AI platform to predict, improve patient flow

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.